{
  "metadata": {
    "case_id": 93,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T19:34:01.334654",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/93_NCT02313272.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/93_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.99
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.99,
          "status": "matched",
          "ref_item": {
            "label": "HFSRT with Pembrolizumab and Bevacizumab",
            "type": "EXPERIMENTAL",
            "description": "Hypofractionated Stereotactic Irradiation (HFSRT). Pembrolizumab intravenous (IV) infusion every 3 weeks. Bevacizumab administered intravenously every 2 weeks.",
            "interventionNames": [
              "Radiation: Hypofractionated Stereotactic Irradiation (HFSRT)",
              "Drug: Pembrolizumab",
              "Drug: Bevacizumab"
            ]
          },
          "pred_item": {
            "label": "HFSRT + Bevacizumab + Pembrolizumab",
            "type": "EXPERIMENTAL",
            "description": "Patients with recurrent high-grade glioma treated with a combination of hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab, and pembrolizumab.",
            "interventionNames": [
              "Radiation: HFSRT",
              "Biological: Bevacizumab",
              "Biological: Pembrolizumab"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.95,
          0.4,
          0.35
        ],
        [
          0.25,
          0.6,
          0.96
        ],
        [
          0.2,
          0.98,
          0.4
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "type": "RADIATION",
            "name": "Hypofractionated Stereotactic Irradiation (HFSRT)",
            "description": "Radiation therapy treatment (FSRT) which will be given to participants over 5 days.",
            "armGroupLabels": [
              "HFSRT with Pembrolizumab and Bevacizumab"
            ]
          },
          "pred_item": {
            "type": "RADIATION",
            "name": "HFSRT",
            "description": "Hypofractionated stereotactic radiotherapy delivered as >= 6 Gy x 5 in five consecutive, daily fractions. Prescribed as 30–35 Gy to the planning target volume (PTV) with a simultaneously integrated boost to the gross tumor volume (GTV) of D95% = 30-40 Gy.",
            "armGroupLabels": [
              "HFSRT + Bevacizumab + Pembrolizumab"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Pembrolizumab",
            "description": "Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.\n\nDose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase.",
            "armGroupLabels": [
              "HFSRT with Pembrolizumab and Bevacizumab"
            ],
            "otherNames": [
              "Keytruda®",
              "MK-3475"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "Pembrolizumab",
            "description": "Anti PD1 antibody administered at 100 mg or 200 mg, intravenously applied every 3 weeks until progression.",
            "armGroupLabels": [
              "HFSRT + Bevacizumab + Pembrolizumab"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Bevacizumab",
            "description": "Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a \\> 10% change in weight.",
            "armGroupLabels": [
              "HFSRT with Pembrolizumab and Bevacizumab"
            ],
            "otherNames": [
              "Avastin®"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "Bevacizumab",
            "description": "VEGF inhibitor administered at 10 mg/kg, intravenously delivered every 2 weeks.",
            "armGroupLabels": [
              "HFSRT + Bevacizumab + Pembrolizumab"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.78
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "measure": "Maximum Tolerated Dose (MTD)",
            "description": "The pembrolizumab dose used in the dose expansion cohort will be MTD determined from the dose escalation phase. Dose Escalation: The maximum tolerated dose (MTD) is the highest dose of pembrolizumab in combination with bevacizumab after radiation therapy that does not cause unacceptable toxicity in more than one of six patients at that dose level. The MTD is defined as one dose level below the highest toxic dose (i.e., the Dose Limiting Toxicity (DLT) dose).",
            "timeFrame": "Up to 24 months"
          },
          "pred_item": {
            "measure": "Safety (Adversarial side effects)",
            "description": "Assessment of adversarial side effects for the protocol combining hypofractionated stereotactic radiotherapy (HFSRT) with bevacizumab and pembrolizumab.",
            "timeFrame": "Not specified"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.42,
          0.6
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.6,
          "status": "matched",
          "ref_item": {
            "measure": "Response Rate (RR)",
            "description": "Response rate of pembrolizumab given in combination with bevacizumab and hypofractionated stereotactic re-irradiation of recurrent high grade gliomas. Response to treatment will be assessed by the investigator and according to the Response Assessment Criteria for High-Grade Gliomas (RANO Criteria). Brain MRI will be performed every 6 weeks beginning at the end of Week 6 (± 1 week) for 3 cycles and then every 12 weeks (± 1 week) until disease progression or treatment discontinuation, whichever occurs later.",
            "timeFrame": "Up to 24 months"
          },
          "pred_item": {
            "measure": "Tumor volume",
            "description": "Assessed using T1-weighted, contrast enhanced magnetic resonance imaging (T1 post). The region of hyperintensity was contoured as the Gross Tumor Volume (GTV).",
            "timeFrame": "Pre-treatment and approximately every 6 weeks (median 42 days)"
          }
        }
      ]
    }
  ]
}